低分子肝素治疗进展型脑梗死的临床研究

Clinical study of low molecular weight heparin on progressive cerebral infarction

目的探讨低分子肝素治疗进展型脑梗死的临床疗效。方法选取我院于2012年3月～2013年8月收治的80例进展型脑梗死患者，并将所有患者随机分成对照组和治疗组。对照组给予常规治疗，而治疗组在常规治疗的基础上给予低分子肝素进行治疗。疗程为1个月。1个疗程后对比两组患者的神经功能缺损评分进行比较。结果对照组的总有效率为75％，治疗组的总有效率为92．5％，治疗组的总有效率明显优于对照组，且并发症的发生率低于对照组。结论对进展型脑梗死患者给予低分子肝素进行治疗具有良好的临床疗效，能够改善患者的病情且安全可靠，有助于提高患者的生活质量，值得在临床上进一步推广。

Objective To investigate the clinical effect of low molecular weight heparin on progressive cerebral infarction. Methods 80 progressive cerebral infarction patients were selected in our hospital from 2012 March to 2013 August,and all patients were randomly divided into control group and treatment group. The control group was given routine treatment,while the treatment group in the conventional treatment based on the given low molecular heparin treatment.Treatment for a month. Neural function defect score after one course of treatment were compared between two groups. Results In the control group in the total efficiency of 75%, the total effective rate in treatment group was 92.5%,the total effective rate in treatment group was significantly better than the control group,and the incidence of complications was lower than the control group. Conclusion The patients with progressive cerebral infarction treated with low molecular weight heparin has good clinical curative effect treatment, can improve the patient＇s condition is safe and reliable,is helpful to improve the quality of life of patients,is worthy of further promotion in clinical.